AMRA Medical has received FDA clearance for AMRA Profiler, now available for use in a clinical setting in the US.
AMRA Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements.
“We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure,” stated Eric Converse, CEO of AMRA. “AMRA Profiler helps address these challenges by providing physicians with the most detailed body composition assessment and imaging available, cost-effectively and with minimal intrusion to the patient. Ultimately this enables clinicians to make more informed treatment decisions about the whole body. This clearance is the next step in our journey of translating the benefits of AMRA into clinical practice and in ultimately contributing to the real world data and real world evidence that are playing an increasing role in health care decisions today.”
AMRA Profiler provides a number of body composition measurements, such as visceral adipose tissue volume, subcutaneous adipose tissue volume, liver fat fraction, and thigh muscle volume, alongside associated medical images. These body composition measurements and images, when interpreted by a trained physician, may yield information that assists in diagnosis.
